Thrombomodulin Mitigates the Progression of Hepatocellular Carcinoma in Steatotic Liver
Journal of Hepatocellular Carcinoma · 2026-02 · Volume 13 · 1-13
DOI: 10.2147/jhc.s568564 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Hepatocellular Carcinoma, 2026-02. Verfasst von Megumi Yamaguchi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Research, Kure Medical Center and Chugoku Cancer Center, National Hospital Organization, Hiroshima, Japan. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Introduction
Metabolic dysfunction associated steatotic liver disease promotes intrahepatic metastasis of liver cancer, although not uniformly. However, the mechanisms underlying steatosis-induced progression of liver cancer are not well understood. Antitumor properties of thrombomodulin (TM) are unknown. We aimed to investigate whether TM contributes to the suppression of hepatocellular carcinoma (HCC) progression in the steatotic livers of mice.
Methods
Mice were fed a normal or choline-deficient diet (CDD) for 4 weeks, followed by splenic injection of mouse Hepa1-6 cells. Hepatic tumors were analyzed 3 weeks after the injection.
Results
CDD induced hepatic steatosis, which resulted in a hypoxic state and the downregulation of TM in the liver. CDD-induced hepatic steatosis promoted HCC progression and increased serum levels of high motility group box 1 (HMGB-1), which were suppressed by recombinant TM (rTM). However, HCC progression was not promoted in non-steatotic livers. In TM+/- mice with hepatic steatosis, of which endogenous TM was severely down-regulated, ischemia-reperfusion significantly enhanced HCC progression compared to that in wild-type mice with steatotic livers, both of which were also ameliorated by rTM. In vitro, hypoxia promoted Hepa1-6 cell motility and secretion of HMGB-1 from the Hepa1-6 cells, and the addition of HMGB-1 also enhanced the motility of the Hepa1-6 cells in the non-hypoxic state, which was suppressed by rTM and anti-HMGB-1 antibodies.
Discussion
These findings suggest that hepatic steatosis has a prometastatic effect through the downregulation of TM. TM has a tumor-suppressive function via the inhibition of HMGB-1 activity. Steatotic liver reduces the expression of TM and accelerated the progression of HCC by decreasing the capacity of TM to absorb HMGB-1. rTM may be a useful modality to prevent HCC progression in steatotic livers during hepatic surgery.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Research, Kure Medical Center and Chugoku Cancer Center, National Hospital Organization, Hiroshima, Japan.
- Department of Surgery, Kure Medical Center and Chugoku Cancer Center, National Hospital Organization, Hiroshima, Japan.
- Department of Gastroenterological and Transplant Surgery, Hiroshima University Hospital, Hiroshima, Japan.
- Department of Clinical and Molecular Genetics, Hiroshima University Hospital, Hiroshima, Japan.
- Genome Medical Center, Shizuoka City Shizuoka Hospital, Shizuoka, Japan.
ORCID-Profile: Tsuyoshi Kobayashi, Goichi Honda
Zitieren
APA
Yamaguchi, M., Tashiro, H., Kuroda, S., Kobayashi, T., Hinoi, T., Honda, G., & Ohdan, H. (2026). Thrombomodulin Mitigates the Progression of Hepatocellular Carcinoma in Steatotic Liver. Journal of Hepatocellular Carcinoma, Volume 13, 1-13. https://doi.org/10.2147/jhc.s568564
Vancouver
Yamaguchi M, Tashiro H, Kuroda S, Kobayashi T, Hinoi T, Honda G, et al. Thrombomodulin Mitigates the Progression of Hepatocellular Carcinoma in Steatotic Liver. Journal of Hepatocellular Carcinoma. 2026;Volume 13:1-13. doi:10.2147/jhc.s568564
BibTeX
@article{Yamaguchi2026,
author = {Yamaguchi, Megumi and Tashiro, Hirotaka and Kuroda, Shintaro and Kobayashi, Tsuyoshi and Hinoi, Takao and Honda, Goichi and Ohdan, Hideki},
title = {Thrombomodulin Mitigates the Progression of Hepatocellular Carcinoma in Steatotic Liver},
journal = {Journal of Hepatocellular Carcinoma},
year = {2026},
volume = {Volume 13},
pages = {1--13},
doi = {10.2147/jhc.s568564}
}
EUVIMED